Literature DB >> 11588044

Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome.

J J Bleesing1, M R Brown, S E Straus, J K Dale, R M Siegel, M Johnson, M J Lenardo, J M Puck, T A Fleisher.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) type Ia is caused by inherited defects in apoptosis and is characterized by nonmalignant lymphoaccumulation, autoimmunity, and increased alpha/beta(+) double-negative T cells (alpha/beta(+)-DNT cells). This study reports immunophenotypic findings in 166 members of 31 families with ALPS type Ia, associated with genetic mutations in the TNFRSF6 gene encoding Fas. The ALPS type Ia probands (n = 31) and relatives having both a Fas mutation and clinically proven ALPS (n = 28) showed significant expansion of CD8(+) T cells, alpha/beta(+)-DNT cells, gamma/delta(+)-DNT cells, CD3(+)/ HLA-DR(+) T cells, CD8(+)/CD57(+) T cells, and CD5(+) B cells. Relatives with Fas mutations, but without all the required criteria for ALPS (n = 42), had expansions of CD8(+) T cells, alpha/beta(+)-DNT cells, and gamma/delta(+)-DNT cells. Interestingly, relatives without a Fas mutation and with no features of ALPS (n = 65) demonstrated a small but significant expansion of CD8(+) T cells, both DNT cell subsets, and CD5(+) B cells. As compared to unrelated healthy controls, lymphocyte subset alterations were greatest in the probands, followed by the relatives with mutations and ALPS. Probands and relatives with mutations and ALPS also showed a lower number of CD4(+)/CD25(+) T cells that, in combination with an independent increase in HLA-DR(+) T cells, provided a profile predictive of the presence of clinical ALPS. Because quantitative defects in apoptosis were similar in mutation-positive relatives regardless of the presence of clinical ALPS, factors, other than modifiers of the Fas apoptosis pathway, leading to these distinctive immunophenotypic profiles most likely contribute to disease penetrance in ALPS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588044     DOI: 10.1182/blood.v98.8.2466

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

Review 1.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

Review 3.  Flow cytometry in hematological disorders.

Authors:  Hara Prasad Pati; Sonal Jain
Journal:  Indian J Pediatr       Date:  2013-08-13       Impact factor: 1.967

Review 4.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

Review 5.  Laboratory diagnosis of primary immunodeficiencies.

Authors:  Bradley A Locke; Trivikram Dasu; James W Verbsky
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

6.  In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation.

Authors:  Jordan R Hansford; Manika Pal; Nicola Poplawski; Eric Haan; Bernadette Boog; Antonio Ferrante; Joie Davis; Julie E Niemela; V Koneti Rao; Ram Suppiah
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 7.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

8.  Exposure to inorganic mercury in vivo attenuates extrinsic apoptotic signaling in Staphylococcal aureus enterotoxin B stimulated T-cells.

Authors:  Michael D Laiosa; Kevin G Eckles; Margaret Langdon; Allen J Rosenspire; Michael J McCabe
Journal:  Toxicol Appl Pharmacol       Date:  2007-06-19       Impact factor: 4.219

9.  Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

Review 10.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.